Shanghai Haohai Biological Technology (688366) Stock Overview

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products comprising intraocular lens, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, soft contact lens, medical sodium hyaluronate gels, injectors, scalpels, suture needles, and other products; orthopedics products, such as sodium hyaluronate injection and medical chitosan products; and anti-adhesion products, including medical sodium hyaluronate gel, and medical chitosan and collagen sponge products. The company also provides medical aesthetics products comprising Matrifill, a first-generation hyaluronic acid (HA) dermal filler, which is a mono-phase sodium hyaluronate gel for injection; Janlane, a second-generation HA dermal filler for dynamic filling function; Hyalumatrix, a third-generation HA dermal filler that offers precise embellishment function; genetic-engineering preparations for epidermal repair; recombinant human epidermal growth factor products; and radio frequency devices and laser equipment. In addition, it is involved in the research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services; sale of professional life and home cosmetology machines; and manufacture and sale of biological reagents, biologicals and biological materials, and other machines and accessories. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.